Parkinson's disease

17 · 20 / page

Ask MedXY AI

Latest news

Tag

NeurologyD1/D5 agonistMotor symptoms

Tavapadon in Early Parkinson’s Disease: Promising Phase 3 Trial Highlights Safety and Motor Symptom Benefits

By MedXY|Aug 9, 2026

The phase 3 TEMPO-2 trial demonstrates that flexible-dose tavapadon, a selective D1/D5 dopamine receptor agonist, significantly improves motor symptoms in early Parkinson’s disease with a manageable safety profile, warranting further

Parkinson’s Disease Genetics Across Diverse Ancestries: An Observational Genetic Study of Causal and Risk Variants with Translational Implications

Clinical Updatesgenetics

Parkinson's disease

Latest news

Tavapadon in Early Parkinson’s Disease: Promising Phase 3 Trial Highlights Safety and Motor Symptom Benefits

Parkinson’s Disease Genetics Across Diverse Ancestries: An Observational Genetic Study of Causal and Risk Variants with Translational Implications

Safety and Efficacy of Staged, Bilateral MRgFUS Pallidothalamic Tractotomy in Parkinson’s Disease Motor Complications: A Contemporary Evidence Review

Selective D1/D5 Agonism: TEMPO-3 Trial Positions Tavapadon as a Significant Advancement for Parkinson’s Motor Fluctuations

The Smart Thermostat for the Brain: How Adaptive DBS is Redefining Parkinson’s Treatment

The Evolving Genetic Landscape of Parkinson’s Disease: Global Prevalence, Phenotypic Correlations, and the Precision Medicine Imperative

Beyond a Positive Result: α-Synuclein Seeding Kinetics Predict Cognitive Decline in Parkinson’s Disease

Azathioprine in Early Parkinson’s Disease: Trial Fails Primary Endpoint but Reveals Sex-Specific Immune Signals

SGLT2 Inhibitors Linked to Lower Parkinson’s Disease Risk Than Metformin in Type 2 Diabetes: Large Real‑World TriNetX Study Signals Class Neuroprotection

APOE ε4 Allele as an Independent Predictor of Survival in Parkinson’s Disease Patients

Microbiome Virulence Signatures in the Oral-Gut-Brain Axis: New Insights into Parkinson’s Disease and Cognitive Decline

Circulating Nanoparticles and Carotenoids as Biomarkers of Rehabilitation Recovery in Parkinson’s Disease

Long-Term Safety and Effectiveness of Personalized Adaptive Deep Brain Stimulation in Parkinson’s Disease

Metabolic Syndrome Increases Parkinson’s Disease Risk: Implications for Clinical Practice and Prevention

Unlocking Parkinson’s Prognosis: The Role of α-Synuclein Seed Amplification Kinetics

Medium‑Chain Triglyceride–Supplemented Ketogenic Diet in Parkinson’s Disease: A Small Randomized Feasibility Trial and What It Means for Clinical Practice

AI-Powered Smile Analysis: A Breakthrough in Parkinson’s Disease Screening